{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T13:52:53Z","timestamp":1778075573405,"version":"3.51.4"},"reference-count":15,"publisher":"American Academy of Pediatrics (AAP)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,6,1]]},"abstract":"<jats:p>We describe here the case of an adolescent who developed eosinophilic hepatitis during treatment for attention-deficit\/hyperactivity disorder with lisdexamfetamine dimesylate (Vyvanse [Shire US Inc, Wayne, PA]). A 14-year-old boy presented to his primary care provider with abdominal pain and worsening jaundice. A diagnosis of hepatitis was made with biochemical markers, but evaluation failed to provide an etiology. Worsening hepatitis prompted hospitalization and initiation of steroids for presumed autoimmune hepatitis. A subsequent liver biopsy showed evidence of eosinophilic hepatitis. Known causes of eosinophilic hepatitis were ruled out, and a presumptive diagnosis of reaction to lisdexamfetamine dimesylate was made. Discontinuation of the medication led to resolution of the hepatitis and normalization of the liver biopsy. To our knowledge, this is the first report of hepatic injury attributed to lisdexamfetamine dimesylate.<\/jats:p>","DOI":"10.1542\/peds.2009-1835","type":"journal-article","created":{"date-parts":[[2010,5,11]],"date-time":"2010-05-11T03:09:14Z","timestamp":1273547354000},"page":"e1510-e1513","source":"Crossref","is-referenced-by-count":12,"title":["Eosinophilic Hepatitis in an Adolescent During Lisdexamfetamine Dimesylate Treatment for ADHD"],"prefix":"10.1542","volume":"125","author":[{"given":"Brandy","family":"Hood","sequence":"first","affiliation":[{"name":"Pediatric Gastroenterology, University of Mississippi Medical Center, Jackson, Mississippi"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J.","family":"Nowicki","sequence":"additional","affiliation":[{"name":"Pediatric Gastroenterology, University of Mississippi Medical Center, Jackson, Mississippi"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"417","published-online":{"date-parts":[[2010,6,1]]},"reference":[{"issue":"234","key":"2021120905335320500_B1","first-page":"1","article-title":"Summary health statistics for U.S. children: National Health Interview Survey, 2006","author":"Bloom","year":"2007","journal-title":"Vital Health Stat 10"},{"issue":"8","key":"2021120905335320500_B2","first-page":"657","article-title":"Current strategies in the diagnosis and treatment of childhood attention-deficit\/hyperactivity disorder","volume":"79","author":"Rader","year":"2009","journal-title":"Am Fam Physician"},{"issue":"1","key":"2021120905335320500_B3","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1124\/dmd.106.011973","article-title":"An evaluation of the cytochrome P450 inhibition potential of lisdexamfetamine in human liver microsomes","volume":"35","author":"Krishnan","year":"2007","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"2021120905335320500_B4","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/S0149-2918(07)80083-X","article-title":"Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit\/hyperactivity disorder: a phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study","volume":"29","author":"Biederman","year":"2007","journal-title":"Clin Ther"},{"issue":"2","key":"2021120905335320500_B5","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"2021120905335320500_B6","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1111\/j.1365-2125.2008.03264.x","article-title":"Causality assessment in hepatotoxicity by drugs and dietary supplements","volume":"66","author":"Teschke","year":"2008","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"2021120905335320500_B7","doi-asserted-by":"crossref","first-page":"169","DOI":"10.2165\/00002018-200831020-00006","article-title":"A surveillance method for the early identification of idiosyncratic adverse drug reactions","volume":"31","author":"Etwel","year":"2008","journal-title":"Drug Saf"},{"issue":"5","key":"2021120905335320500_B8","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/S0022-3476(98)70329-4","article-title":"Pemoline hepatotoxicity in children","volume":"132","author":"Marotta","year":"1998","journal-title":"J Pediatr"},{"issue":"4","key":"2021120905335320500_B9","doi-asserted-by":"crossref","first-page":"345","DOI":"10.2165\/00002018-200831040-00008","article-title":"Hepatic events associated with atomoxetine treatment for attention-deficit hyperactivity disorder","volume":"31","author":"Bangs","year":"2008","journal-title":"Drug Saf"},{"issue":"6","key":"2021120905335320500_B10","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.jpeds.2006.01.035","article-title":"Severe liver injury after initiating therapy with atomoxetine in two children","volume":"148","author":"Lim","year":"2006","journal-title":"J Pediatr"},{"issue":"5","key":"2021120905335320500_B11","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1084\/jem.161.5.1231","article-title":"Anti-liver-kidney microsome antibody recognizes a 50,000 molecular weight protein","volume":"161","author":"Alvarez","year":"1985","journal-title":"J Exp Med"},{"issue":"11","key":"2021120905335320500_B12","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1345\/aph.1E162","article-title":"Recurrent acute hepatitis associated with use of cetirizine","volume":"38","author":"Pompili","year":"2004","journal-title":"Ann Pharmacother"},{"issue":"2","key":"2021120905335320500_B13","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1046\/j.1365-2036.1999.00454.x","article-title":"Review article: mechanisms and management of hepatotoxicity in ecstasy (MDMA) and amphetamine intoxications","volume":"13","author":"Jones","year":"1999","journal-title":"Aliment Pharmacol Ther"},{"issue":"7","key":"2021120905335320500_B14","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1080\/004982599238344","article-title":"Involvement of CYP2D6 in the in vitro metabolism of amphetamine, two N-alkylamphetamines and their 4-methoxylated derivatives","volume":"29","author":"Bach","year":"1999","journal-title":"Xenobiotica"},{"issue":"1","key":"2021120905335320500_B15","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1080\/15563650600795644","article-title":"Atomoxetine-induced hepatitis in a child","volume":"45","author":"Stojanovski","year":"2007","journal-title":"Clin Toxicol (Phila)"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/125\/6\/e1510\/1089645\/zpe006100e1510.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/125\/6\/e1510\/1089645\/zpe006100e1510.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,9]],"date-time":"2021-12-09T23:08:47Z","timestamp":1639091327000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/125\/6\/e1510\/72480\/Eosinophilic-Hepatitis-in-an-Adolescent-During"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6,1]]},"references-count":15,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2010,6,1]]},"published-print":{"date-parts":[[2010,6,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2009-1835","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,6,1]]}}}